Alpha 2.0
Login Register
» Authors » Carlos Vrech

Carlos Vrech

Explore the profile of Carlos Vrech including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 105
Followers 0
Related Specialties
Neurology
General Medicine
Pharmacology
Top 10 Co-Authors
Liliana Patrucco
Edgardo Cristiano
Edgar Carnero Contentti
Ricardo Alonso
Norma Deri
Jimena Miguez
Veronica Tkachuk
Nora Fernandez Liguori
Marcos Burgos
Dario Tavolini
Published In
Mult Scler Relat Disord
J Neurol Sci
Neurol Sci
Mult Scler J Exp Transl Clin
Medicina (B Aires)
Affiliations
Soon will be listed here.
Recent Articles
1.
Additional Cladribine tablets treatment courses in multiple sclerosis patients. A retrospective observational study in Latin American countries
Silva B, Ysrraelit M, Zanga G, Segamarchi M, Cragnolini C, Galleguillos L, et al.
Mult Scler Relat Disord . 2025 Jan; 94:106275. PMID: 39847855
The use of additional cladribine tablets treatment courses is becoming an option in patients with multiple sclerosis (MS) showing disease activity after treatment initiation. Despite the availability over the past...
2.
Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM)
Carnero Contentti E, Lopez P, Patrucco L, Cristiano E, Miguez J, Silva B, et al.
Mult Scler Relat Disord . 2024 Jul; 89():105771. PMID: 39033591
Background: Immunosuppressive therapies as azathioprine (AZA), mycophenolate mofetil (MMF) and rituximab (RTX) are widely prescribed as first-line treatment to prevent relapses in NMOSD. However, the rate of response to these...
3.
Real-World Effectiveness and Safety of Cladribine in Multiple Sclerosis: Longitudinal Data From the Nationwide Registry in Argentina
Rojas J, Alonso R, Luetic G, Patrucco L, Casas M, Silva B, et al.
Clin Neuropharmacol . 2024 Jul; 47(4):120-127. PMID: 39008542
Objective: The aim was to evaluate patient profiles, effectiveness and safety of cladribine (CLAD) in patients with relapsing-remitting multiple sclerosis in Argentina. Methods: This was a substudy included in RelevarEM...
4.
Treatment strategies and responses for attacks of neuromyelitis optica spectrum disorder: A real-world retrospective cohort study
Carnero Contentti E, Lopez P, Pettinicchi J, Miguez J, Patrucco L, Cristiano E, et al.
J Neurol Sci . 2024 Jun; 462:123099. PMID: 38897155
Methods: We conducted a retrospective study involving NMOSD patients from the Argentinean MS and NMOSD registry (RelevarEM, NCT03375177). Treatment response at 6 months was categorized as "good" if the EDSS...
5.
Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry
Piedrabuena M, Correale J, Fiol M, Marrodan M, Rojas J, Alonso M, et al.
J Neurol Sci . 2024 May; 461:123052. PMID: 38797140
Background: Knowledge of the safety and efficacy of disease-modifying therapies (DMTs) in older patients with Multiple Sclerosis (pwMS) is limited due to their exclusion from clinical trials. Our purpose is...
6.
Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings
Pestchanker C, Bertado Cortez B, Lana Peixoto M, Gortari J, Castro Suarez S, Caparo Zamalloa C, et al.
J Neurol . 2024 Apr; 271(7):4292-4299. PMID: 38630312
Introduction: We aimed to assess the frequency, duration, and severity of area postrema syndrome (APS) during follow-up in neuromyelitis optica spectrum disorder (NMOSD) patients, as well as its association with...
7.
Clinical characterization of long-term multiple sclerosis (COLuMbus) patients in Argentina: A cross-sectional non-interventional study
Deri N, Barboza A, Vrech C, Rey R, Burgos M, Fiol M, et al.
Mult Scler Relat Disord . 2024 Jan; 83:105421. PMID: 38244525
Background: Most Multiple Sclerosis (MS) clinical trials fail to assess the long-term effects of disease-modifying therapies (DMT) or disability. Methods: COLuMbus was a single-visit, cross-sectional study in Argentina in adult...
8.
Incidence of SARS-CoV-2 infection in patients with multiple sclerosis who received SARS-CoV-2 vaccines and are under treatment with high-efficacy therapies in Argentina
Carnero Contentti E, Lopez P, Pappolla A, Alonso R, Silva B, Deri N, et al.
Neurol Sci . 2023 Dec; 45(2):379-389. PMID: 38159147
Methods: Non-interventional, retrospective cohort study that collected information directly from RelevarEM. Adult PwMS who had been treated for at least 6 months with a HET (ocrelizumab, natalizumab, alemtuzumab, cladribine) who...
9.
Mortality of neuromyelitis optica spectrum disorder patients in an Argentinean population: A study from the RelevarEM registry
Carnero Contentti E, Lopez P, Pettinicchi J, Criniti J, Pappolla A, Miguez J, et al.
Mult Scler J Exp Transl Clin . 2023 Oct; 9(4):20552173231205444. PMID: 37854639
We aimed to evaluate mortality and causes of death among Argentinean neuromyelitis optica spectrum disorder (NMOSD) patients and identify predictors of death. Retrospective study included 158 NMOSD patients and 11...
10.
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina
Alonso R, Casas M, Lazaro L, Fernandez Liguori N, Pita C, Cohen L, et al.
Mult Scler Relat Disord . 2023 Aug; 79:104935. PMID: 37634468
Background: Disease-modifying therapies (DMTs) in multiple sclerosis (MS) can be classified according to the efficacy in which they prevent inflammatory activity. To date, there are limited data regarding the use...